ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements with these filters
Genpharmasec's Company Secretary and Compliance Officer Hardik Makwana resigned, effective 16 November 2026. The resignation reflects a senior key managerial personnel departure, citing other professional opportunities.
Genpharmasec approved unaudited half-year results and planned sale of its wholly owned subsidiary Clinigenome India. Company Secretary Hardik Makwana resigns effective 16 November 2026.
Genpharmasec Ltd will hold a Board meeting on 03 Nov 2026. Agenda includes proposing approval of Q2/H1 FY27 unaudited results.
Genpharmasec Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing provides a standard breakdown of promoter and public shareholding.
Genpharmasec Limited conducted its 34th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including the adoption of FY26 financial statements and director re-appointments.
Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.
Genpharmasec Limited has re-appointed Sohan Chaturvedi as Executive Director for a 36-month term effective April 26, 2027. This change is approved by the Board.
Genpharmasec Limited has announced the closure of its share transfer books from September 23 to 29, 2026, for the 34th Annual General Meeting.
Genpharmasec Limited announced the schedule for its 34th Annual General Meeting and approved the re-appointment of Mr. Sohan Chaturvedi as Whole Time Director.
Promoter and Director Rajesh Sadhwani acquired 65,00,000 equity shares via market purchase. This increases his stake from 14.09% to 15.26% in Genpharmasec Ltd.
Promoter and Director Rajesh Sadhwani acquired 50 lakh equity shares worth Rs. 0.505 Crore in Genpharmasec Ltd via market purchase.
Promoter Rajesh Mirchumal Sadhwani acquired 50,00,000 shares (0.90%) of Genpharmasec Ltd through an open market purchase. This transaction increases the promoter group's total stake to 30.88%.
Genpharmasec Ltd has scheduled a board meeting for September 2, 2026. The meeting will primarily focus on finalizing details for the upcoming 34th Annual General Meeting.
Genpharmasec Limited has been appointed as a non-exclusive Super Stockist by Amneal Healthcare Private Limited. The agreement includes a minimum annual sales commitment of ₹75 Crore.
Genpharmasec Ltd reported revenue from operations of ₹49.7 Cr (+314.2% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.
Genpharmasec Ltd scheduled a board meeting for August 11, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Genpharmasec Limited filed its Annual Secretarial Compliance Report for FY 2025-26. The auditor reported full compliance with SEBI regulations, noting no material deviations or penalties.
Genpharmasec Ltd reported zero deviation in the utilization of its ₹48.45 Crore Rights Issue proceeds. The funds were deployed according to the stated objects.
Genpharmasec Ltd reported revenue from operations of ₹55.4 Cr (+295.7% YoY) and net profit of ₹1.4 Cr for Q4 FY26.
Genpharmasec Limited reported its audited standalone and consolidated financial results for fiscal year 2026. The board also re-appointed M/s. Abhishek M Agrawal & Co. as internal auditors.
Genpharmasec Limited scheduled a board meeting for May 21, 2026. Directors will consider and approve audited financial results for the fiscal year ended March 2026.